Abstract: The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders.

Abstract: Presented herein is a methodology for reducing weight in obese subjects and in patients receiving various medical treatments that are accompanied with weight gain. The methodology allows for management of weight gain, management of triglyceride levels and weight reduction in obese subjects.

Abstract: The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders.

Abstract: The present invention provides a compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR6, OC(O)R6, C(O)R6 C(S)R6, CO2R6, C(O)SR6, C(O)NR6R7, C(S)NR6R7, NR6R7, NR6C(O)R7, NR6C(S)R7, NR6C(O)NR7R8, NR6C(S)NR7R8, NR6SO2R7, NR6SO2NR7R8, SR6, SC(O)R6, SC(O)NR6R7, S(O)R6, SO2R6, SO2NR6R7, or NR6SO2R7R8. Also provided is a pharmaceutical composition that includes one or more compounds of the present invention, and methods of therapeutically using and processes for producing such compounds and compositions.

Abstract: The present invention provides a method for treating or preventing a disease or disorder treatable by the inhibition of serotonin reuptake in a patient, and/or norepinephrine reuptake and/or dopamine reuptake in a patient, the method comprising administering to the patient a neurotransmitter reuptake inhibiting-effective amount of at least one compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogean halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR6, OC(O)R6, C(O)R6, C(S)R6, CO2R6, C(O)SR6, C(O)NR6R7, C(S)NR6R7, NR6R7, NR6C(O)R7, NR6C(S)R7, NR6C(O)NR7R8, NR6C(S)NR7R8, NR6SO2R7, NR6SO2NR7R8, SR6, SC(O)R6, SC(O)NR6R7, S(O)R6, SO2R6, SO2NR6R7, or NR6SO2NR7R8.

Abstract: The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders.

Abstract: A method and a composition for the treatment of an Inflammatory Bowel Disease (IBD) or intestine polyposes is described. The method includes the local administration to the colon of a therapeutically effective amount of at least one Selective Serotonin Reuptake Inhibitor (SSRI) or at least one tricyclic antidepressant (TCA).

Abstract: A method and a Cranial Electrical Stimulator CES (4) for operation in a diagnosis, treatment, research, and test mode related to mental disorder, are disclosed. Diagnosis is based on a detected condition of passage of an electric signal via a pathway in the brain defined as passing from a first to a second electrode of a pair of electrodes from an array (12) attached to the skull (6) of a patient. Treatment is achieved by injecting a treatment signal in the pathway detected as having a condition. A practitioner (2) operates a workstation (8) of the CES (4) that controls a signal and routing box SRB (10) generating input signals and receiving output signal from the brain, via the skull (6) and electrodes (12). The PC (14) of the workstation controls signal input, output reception, measurement, display and storage in memory (15).

Abstract: A method and a Cranial Electrical Stimulator CES for operation in a diagnosis, treatment, research, and test mode related to brain disorders, namely to mental disorders, and to neurological disorders, such as migraine and epilepsy, are disclosed. Diagnosis is based on a detected condition of passage of an electric signal via a pathway in the brain defined as passing from a first to a second electrode of a pair of electrodes from an array attached to the skull of a patient. Treatment is achieved by injecting a treatment signal in the pathway detected as having a condition. A practitioner operates a workstation of the CES that controls a signal and routing box SRB generating input signals and receiving output signal from the brain, via the skull and electrodes. The PC of the workstation controls signal input, output reception, measurement, display and storage in memory.

Abstract: A method and a Cranial Electrical Stimulator CES (4) for operation in a diagnosis, treatment, research, and test mode related to mental disorder, are disclosed. Diagnosis is based on a detected condition of passage of an electric signal via a pathway in the brain defined as passing from a first to a second electrode of a pair of electrodes from an array (12) attached to the skull (6) of a patient. Treatment is achieved by injecting a treatment signal in the pathway detected as having a condition.